Table 1.

Patient and primary tumor characteristics

	Total	Curative intent	Palliative intent
	n = 27 n (%)	n = 19 n (%)	n = 8 n (%)
Gender
Male	12 (44)	7 (73)	3 (38)
Female	15 (56)	12 (63)	5 (63)
Age at ILNM diagnosis
Median (IQR)	63 (44–69)	60 (40–69)	64 (57–67)
ASA
ASA 1–2	25 (93)	18 (95)	7 (78)
ASA > 2	2 (7)	1 (5)	1 (13)
Rectal tumor at ILNM diagnosis
Primary	21 (78)	17 (90)	4 (50)
LRRC	6 (22)	2 (11)	4 (50)
Distance from anal verge (cm)
Median (IQR)	2 (1–3)	1 (0–7)	2 (1–3)
Location of rectal tumor
Low rectal (< 5 cm)	22 (82)	14 (74)	8 (100)
Mid rectal (5–10 cm)	3 (11)	3 (16)	0 (0)
High rectal (> 10 cm)	2 (7)	2 (11)	0 (0)
Neoadjuvant therapy for rectal tumor
CTxRTx	18 (67)	14 (74)	4 (50)
RTx	4 (15)	3 (11)	1 (13)
CTx	0 (0.0)	0 (0)	0 (0)
No neoadjuvant therapy	5 (19)	2 (11)	3 (38)
Surgical procedure for primary tumor
No resectiona	2 (5)	2 (11)	0 (0)
LAR	7 (26)	4 (21)	3 (38)
APR	9 (33)	5 (26)	4 (50)
APR with HIPEC	1 (4)	1 (5)	0 (0)
Posterior pelvic exenteration	4 (15)	3 (16)	1 (13)
Total pelvic exenteration	4 (15)	4 (21)	0 (0)
Tumor stage of primary tumor
No resection	2 (8)	2 (11)	0 (0)
T2	3 (11)	2 (11)	1 (13)
T3	11 (41)	7 (37)	4 (50)
T4	11 (41)	8 (42)	3 (38)
Nodal stage of primary tumor
No resection	2 (7)	2 (11)	0 (0)
N0	10 (37)	5 (26)	5 (63)
N1	8 (30)	6 (32)	2 (25)
N2	7 (26)	6 (32)	1 (13)

Numbers do not add up due to rounding

ILNM inguinal lymph node metastases, IQR interquartile range, ASA American Society of Anesthesiology, LRRC locally recurrent rectal cancer, CTxRTx chemoradiotherapy, RTx radiotherapy, CTx chemotherapy, LAR low anterior resection, APR abdominoperineal resection, HIPEC hyperthermic intraperitoneal chemotherapy

^aNo resection due to progressive disease